BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33400301)

  • 1. CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
    Wang HT; Zhu ZA; Li YY; Lou SS; Yang G; Feng X; Xu W; Huang ZL; Cheng X; Xiong ZQ
    Epilepsia; 2021 Feb; 62(2):517-528. PubMed ID: 33400301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
    Mulcahey PJ; Tang S; Takano H; White A; Davila Portillo DR; Kane OM; Marsh ED; Zhou Z; Coulter DA
    Exp Neurol; 2020 Oct; 332():113388. PubMed ID: 32585155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKL5 deficiency in adult glutamatergic neurons alters synaptic activity and causes spontaneous seizures via TrkB signaling.
    Zhu ZA; Li YY; Xu J; Xue H; Feng X; Zhu YC; Xiong ZQ
    Cell Rep; 2023 Oct; 42(10):113202. PubMed ID: 37777961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder.
    Terzic B; Cui Y; Edmondson AC; Tang S; Sarmiento N; Zaitseva D; Marsh ED; Coulter DA; Zhou Z
    Neurobiol Dis; 2021 Jan; 148():105176. PubMed ID: 33197557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A GABA
    Gennaccaro L; Fuchs C; Loi M; Roncacè V; Trazzi S; Ait-Bali Y; Galvani G; Berardi AC; Medici G; Tassinari M; Ren E; Rimondini R; Giustetto M; Aicardi G; Ciani E
    Neurobiol Dis; 2021 Jun; 153():105304. PubMed ID: 33621640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDKL5 Deficiency Augments Inhibitory Input into the Dentate Gyrus That Can Be Reversed by Deep Brain Stimulation.
    Hao S; Wang Q; Tang B; Wu Z; Yang T; Tang J
    J Neurosci; 2021 Oct; 41(43):9031-9046. PubMed ID: 34544833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered NMDAR signaling underlies autistic-like features in mouse models of CDKL5 deficiency disorder.
    Tang S; Terzic B; Wang IJ; Sarmiento N; Sizov K; Cui Y; Takano H; Marsh ED; Zhou Z; Coulter DA
    Nat Commun; 2019 Jun; 10(1):2655. PubMed ID: 31201320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder.
    Yennawar M; White RS; Jensen FE
    J Neurosci; 2019 Jun; 39(24):4814-4828. PubMed ID: 30952813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced hippocampal LTP but normal NMDA receptor and AMPA receptor function in a rat model of CDKL5 deficiency disorder.
    Simões de Oliveira L; O'Leary HE; Nawaz S; Loureiro R; Davenport EC; Baxter P; Louros SR; Dando O; Perkins E; Peltier J; Trost M; Osterweil EK; Hardingham GE; Cousin MA; Chattarji S; Booker SA; Benke TA; Wyllie DJA; Kind PC
    Mol Autism; 2024 Jun; 15(1):28. PubMed ID: 38877552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.
    Galvani G; Mottolese N; Gennaccaro L; Loi M; Medici G; Tassinari M; Fuchs C; Ciani E; Trazzi S
    J Neuroinflammation; 2021 Jul; 18(1):155. PubMed ID: 34238328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDKL5-mediated developmental tuning of neuronal excitability and concomitant regulation of transcriptome.
    Liao W; Lee KZ
    Hum Mol Genet; 2023 Nov; 32(23):3276-3298. PubMed ID: 37688574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mGluR5 PAMs rescue cortical and behavioural defects in a mouse model of CDKL5 deficiency disorder.
    Gurgone A; Pizzo R; Raspanti A; Chiantia G; Devi S; Comai D; Morello N; Pilotto F; Gnavi S; Lupori L; Mazziotti R; Sagona G; Putignano E; Nocentini A; Supuran CT; Marcantoni A; Pizzorusso T; Giustetto M
    Neuropsychopharmacology; 2023 May; 48(6):877-886. PubMed ID: 35945276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormalities of mitochondrial dynamics and bioenergetics in neuronal cells from CDKL5 deficiency disorder.
    Van Bergen NJ; Massey S; Stait T; Ellery M; Reljić B; Formosa LE; Quigley A; Dottori M; Thorburn D; Stroud DA; Christodoulou J
    Neurobiol Dis; 2021 Jul; 155():105370. PubMed ID: 33905871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early-onset brain alterations during postnatal development in a mouse model of CDKL5 deficiency disorder.
    Tassinari M; Uguagliati B; Trazzi S; Cerchier CB; Cavina OV; Mottolese N; Loi M; Candini G; Medici G; Ciani E
    Neurobiol Dis; 2023 Jun; 182():106146. PubMed ID: 37164289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder.
    Katayama S; Sueyoshi N; Inazu T; Kameshita I
    Neural Plast; 2020; 2020():6970190. PubMed ID: 32587608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding the phenotype of the CDKL5 deficiency disorder: Are seizures mandatory?
    MacKay CI; Bick D; Prokop JW; Muñoz I; Rouse J; Downs J; Leonard H
    Am J Med Genet A; 2020 May; 182(5):1217-1222. PubMed ID: 32034940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons.
    Loi M; Trazzi S; Fuchs C; Galvani G; Medici G; Gennaccaro L; Tassinari M; Ciani E
    Mol Neurobiol; 2020 May; 57(5):2244-2262. PubMed ID: 32002787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.
    Fuchs C; Medici G; Trazzi S; Gennaccaro L; Galvani G; Berteotti C; Ren E; Loi M; Ciani E
    Brain Pathol; 2019 Sep; 29(5):658-674. PubMed ID: 30793413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder.
    Fuchs C; Gennaccaro L; Ren E; Galvani G; Trazzi S; Medici G; Loi M; Conway E; Devinsky O; Rimondini R; Ciani E
    Neuropharmacology; 2020 May; 167():107746. PubMed ID: 31469994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder.
    Jhang CL; Lee HY; Chen JC; Liao W
    Hum Mol Genet; 2020 Aug; 29(14):2408-2419. PubMed ID: 32588892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.